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Aims: PKN1 is a stress-responsive protein kinase acting downstream of small GTP-binding 
proteins of the Rho/Rac family. The aim was to determine its role in endogenous 
cardioprotection. 
Methods and Results: Hearts from PKN1 knockout (KO) or wild type (WT) littermate control 
mice were perfused in Langendorff mode and subjected to global ischemia and reperfusion 
(I/R). Myocardial infarct size was doubled in PKN1 KO hearts compared to WT hearts. PKN1 
was basally phosphorylated on the activation loop Thr778 PDK1 target site which was 
unchanged during I/R. However, phosphorylation of p42/p44-MAPK was decreased in KO 
hearts at baseline and during I/R. In cultured neonatal rat ventricular cardiomyocytes (NRVM) 
and NRVM transduced with kinase dead (KD) PKN1 K644R mutant subjected to simulated 
ischaemia/reperfusion (sI/R), PhosTag® gel analysis showed net dephosphorylation of PKN1 
during sI and early R despite Thr778 phosphorylation. siRNA knockdown of PKN1 in NRVM 
significantly decreased cell survival and increased cell injury by sI/R which was reversed by 
WT- or KD-PKN1 expression. Confocal immunofluorescence analysis of PKN1 in NRVM 
showed increased localisation to the sarcoplasmic reticulum (SR) during sI. GC-MS/MS and 
immunoblot analysis of PKN1 immunoprecipitates following sI/R confirmed interaction with 
CamKII. Co-translocation of PKN1 and CamKII to the SR/membrane fraction during sI 
correlated with phospholamban (PLB) Thr17 phosphorylation. siRNA knockdown of PKN1 in 
NRVM resulted in increased basal CamKII activation and increased PLB Thr17 
phosphorylation only during sI. In vivo PLB Thr17 phosphorylation, Sarco-Endoplasmic 
Reticulum Ca2+ ATPase (SERCA2) expression and Junctophilin-2 (Jph2) expression were 
also basally increased in PKN1 KO hearts. Furthermore, in vivo P-V loop analysis of the beat-
to-beat relationship between rate of LV pressure development or relaxation and end diastolic 
P (EDP) showed mild but significant systolic and diastolic dysfunction with preserved ejection 
fraction in PKN1 KO hearts. 
Conclusions: Loss of PKN1 in vivo significantly reduces endogenous cardioprotection and 
increases myocardial infarct size following I/R injury. Cardioprotection by PKN1 is associated 
with reduced CamKII-dependent PLB Thr17 phosphorylation at the SR and therefore may 
stabilise the coupling of SR Ca2+ handling and contractile function, independent of its kinase 
activity. 
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Non-standard abbreviations. 
PKN1  Protein kinase Novel 1 
I/R  Ischemia/reperfusion 
sI/R  Simulated ischemia/reperfusion 
CamKII Calcium-calmodulin-dependent kinase II isoform delta 




SERCA Sarco-endoplasmic reticulum calcium ATPase 
PLB  Phospholamban 
SR  Sarcoplasmic reticulum 
IVC  Inferior vena cava 
 
1. Introduction. 
Myocardial ischemia and reperfusion induce cardiomyocyte injury resulting in cell death-the 
extent of which is dependent on the length of the ischemic insult. The myocardium has innate 
endogenous protective mechanisms which mitigate against injury which are dependent on the 
activation of kinase signalling and contribute to both basal and inducible cardioprotection 1-5. 
PKN1 is a stress-responsive kinase and a member of the protein kinase novel (PKN) family also 
known as protein kinase C-related kinases (PRKs)6, 7. PKNs currently comprise three isoforms, 
PKN1, PKN2 and PKN3 (formerly known as PKN or PKN1, PKN2 and PKN respectively) PKN1 
and PKN2 are expressed ubiquitously7, 8. The C-terminal kinase domains of PKNs are closely 
related to those of PKC, having approximately 50% homology with PKC and PKC, but have a 
quite different regulatory domain, comprising an HR1 (a,b,c) domain, followed by a C2-related 
domain. Overall these proteins have a domain organisation related to that of the yeast PKC-
related proteins9. The HR1 domain interacts with the small GTPases Rho (A,B)10-12 and Rac11-13  
when bound to GTP (ie. in their active state), such that PKNs can act as molecular effectors of 
these small GTPases. The interaction of Rho with PKN1 induces a conformational change in 
PKN1 leading to activation loop phosphorylation by 3-Phosphoinositide-Dependent Kinase-
1(PDK1) on Thr774 in the case of human PKN1 (Thr778 in mouse/rat) which is necessary for the 
catalytic activation of PKN1/2 14 and critical for the stability of the protein 15, 16. Analysis of rat 
liver PKN1 by mass spectroscopy has also revealed numerous additional sites which are 
phosphorylated under basal conditions 17.  Interestingly, many of the phosphorylated serine and 
threonine residues are in the N-terminal regulatory region and the linker region immediately 
upstream of the kinase domain 17.   The functional significance of these sites is not fully 
understood, but may be important in PKN1 localisation. 
Hyper- and hypo-osmotic stress induce Rac1- and RhoA-PDK1-dependent PKN1 
translocation/activation respectively 18-20 and PKN1 catalytic activity may be required for 
turnover/exit from membrane localisation. However, the role of PKN1 in cardiac 
ischemia/reperfusion injury and post-infarction remodelling remains to be explored in detail. 
Other studies have also supported a role for PKN1 in ischemia. A PKN1 constitutively active 
fragment is generated by caspase mediated cleavage of PKN1 under ischaemic conditions in 
vivo 21, 22 and ischemic stress promotes PKN1 translocation from the cytosol to the nucleus 
suggesting that PKN1 may have a role in regulating gene expression 23.  
Recent work has shown that cardiomyocyte-specific transgenic overexpression of constitutively 
active PKN1 in the heart leads to stable hypertrophy, reduced infarct size and reduced TUNEL 
staining following ischemia/reperfusion, whilst overexpression of dominant negative PKN (K644D) 




has the opposite effect 24. This leads to the conclusion that the protective effect of PKN is cell 
autonomous in cardiomyocytes. The results we show here are that the loss of PKN1 expression 
by homologous recombination reduces basal p42/p44-MAPK (ERK1/2) phosphorylation without 
effect on p38-MAPK or p46/p54-SAPK/JNK activation by ischemia/reperfusion but increases 
infarct size in support of a cardioprotective function for PKN1. In keeping with this, 
overexpression of PKN1 in isolated, cultured cardiac myocytes protected against simulated 
ischemia/reperfusion injury, whereas knockdown of endogenous PKN1 using siRNA increased 
the severity of injury. However, in contrast to 24, loss of kinase activity by introduction of a K644R 
mutation did not alter the protective effect of PKN1 overexpression. The protective effect of PKN1 
was associated with an SR localisation and association with several ER/SR calcium handling 
proteins including CamKII during ischemia. Furthermore, loss of PKN1 resulted in the increased 
phosphorylation of the CamKII substrate PLB on Thr17 during ischaemia. PKN1 loss in vivo 
resulted in mild systolic and diastolic dysfunction at baseline associated with constitutive PLB 
Thr17 phosphorylation as well as increased levels of the SR Ca2+ pump SERCA2. These results 
suggests a role for PKN1 in the maintenance of SR Ca2+ regulatory processes in normal hearts 
which limits the development of ischemia/reperfusion injury, but that these effects are 
independent of its kinase activity. 
  





All animal experiments were performed in accordance with European Commission and UK 
Home Office guidelines and were approved by the local University animal ethics review 
panel. 
2.1 PKN1 Knockout Mouse 
The PKN1 global knockout (KO) mouse line was generated by homologous recombination 
with insertion of a neomycin cassette into exon 2 of the PKN1 gene. PKN1 knockout mice 
were generated at the Cancer Research UK, London Research Institute (now the Francis 
Crick Institute), Lincoln’s Inn Fields, London as previously described 25. 
2.2 Antibodies 
Monoclonal primary antibody against PKN1 was obtained from BD-Transduction Labs, UK.  
Polyclonal antibodies for phospho-PRK1 (Thr774)/PRK2 (Thr816), DYKDDDK (FLAG®), Nogo-
A, phospho-Erk (Thr202/Tyr204), Erk 1/2, phospho-JNK (Thr183/Tyr185), JNK, phospho-p38 
(Thr180/Tyr182), p38, GAPDH were from Cell Signalling Technologies, UK.  Polyclonal 
antibody against p-CamKII (Thr287) was from Life Technologies, UK. Polyclonal antibodies 
against CamKII and Jph2 were from Abcam, UK. Polyclonal antibodies against SERCA2a, 
phospho-phospholamban (Thr17), and total phospholamban were from Badrilla, UK. 
Monoclonal antibody against Na+/K+ATPase alpha (NKA) was from ThermoFisher, UK. 
Monoclonal sarcomeric α-actinin antibody was   obtained from Sigma-Aldrich, UK.   Cy3- and 
Cy5-congugate antibodies were from Jackson Laboratories.  
2.3 Plasmid Constructs 
A construct encoding human PKN1 cDNA with a C-terminal FLAG® tag was generated using 
a GFP-PKN1 template plasmid 18.   PKN1 was amplified using primer 1: 5’-
GCGCAAGCTTGCATGGCCAGCGACGCCGTGC-3’ and primer 2:5’-
TCAATGTACGGTACCTCTACTTATCGTCGTCATCCTTGTAATCGCAGCC-3’.  Primer 1 
incorporates a HindIII restriction site whereas primer 2 encodes a FLAG® epitope and a Kpn1 
restriction site.  The product was digested with HindIII and Kpn1 and subsequently cloned 
into pCMVScript (Promega).  The resulting plasmid contained the full length PKN1 sequence 
fused to a C-terminal FLAG® tag (PKN1_FLAG).   The PKN1_FLAG sequence was 
transferred to a small shuttle plasmid (pDONR221) using the Gateway® cloning technology 
(Life Technologies) according to the manufacturer’s instructions.  Briefly, PKN1_FLAG, the 
CMV promoter and the translation termination sequence from pCMVScript were amplified 
using primer 3: 5’-GGG GAC AAG TTT GTA CAA AAA AGC AGG CTA TGC ATT AGT TAT 
TAA TAG TAA TCA ATT ACG GGG TC-3’ and primer 4: 5’-GGG GAC CAC TTT GTA CAA 
GAA AGC TGG GTC GCG AAT TTT AAC AAA ATA TTA ACG CTT ACA ATT TAC-3’.  
Primers 3 and 4 encode 5’- and 3’- att B sites for subsequent recombination.  The product 
from this step was combined with pDONR221 in the presence of BP Clonase II (Life 
technologies) to generate recombinant pDONR221 encoding PKN1_FLAG and components 
required for its transcription and translation from this plasmid (pDONR-PKN1_FLAG).  The 




kinase dead mutant (KDPKN1_FLAG) was generated by introducing a single mutation 
(K644R) by site directed mutagenises using primer 5: 5’-GGG AGC TGT TCG CCA TCA GGG 
CTC TGA AG-3’ and primer 6: 5’- CTT CAG AGC CCT GAT GGC GAA CAG CTC CC-3’ 
using pDONR-PKN1_FLAG as a template.   As a negative control, an empty vector encoding 
FLAG® but not PKN1 was generated in pDONR221 (mock) using a similar strategy as 
described above.  Finally, to generate adenoviral pacmid constructs, pDONR plasmid 
(PKN1_FLAG, KD-PKN1_FLAG, mock) was recombined with pAd-DESTPL using LR 
Clonase II (Life Technologies) according to the manufacturer’s instructions. Products from 
each step were verified by sequence analysis.     
2.4 Isolation and culture of neonatal rat ventricular myocytes  
Neonatal rats were euthanised by cervical dislocation according to schedule 1 of the UK 
Home Office guidelines. Ventricular cardiomyocytes (NRVMs) were isolated from 1-2 day old 
Sprague-Dawley rat hearts by collagenase/pancreatin digestion as described previously3.  
Cells were plated at a density of approximately 1 x 106 cells/well on gelatin coated 6-well 
plates (NUNC) in medium containing 4:1 DMEM:M199 supplemented with 5% foetal calf 
serum; 10% horse serum and 1% penicillin/streptomycin (GIBCO) for 24 hours and then 
transferred to maintenance medium (MM) (serum-free DMEM:M199 plus antibiotics).   
2.5 RNA Interference studies 
For PKN1 knockdown studies, siRNA or adenovirus harbouring shRNA were used. For siRNA 
experiments commercially available, pre-designed siRNA against rat Pkn1 (Silencer® Select 
4390771) and an siRNA oligomer predicted not to target any known mammalian gene 
(Silencer® Select Negative Control #1) were obtained from Life Technologies. For 
transfection, 15 nM siRNA was complexed with Lipofectamine RNAiMAX (Life Technologies) 
according to the manufacturer’s instructions in Opti-MEM (Life Technologies).  Nuclear 
complexes were applied on cells in 1.0 mL of transfection solution (116 mM NaCl, 1 mM 
NaH2P04, 0.8 mM MgSO4, 5.5 mM glucose, 32.1 mM NaHCO3, 1.8 mM CaCl2, pH7.2) 
supplemented with M199 (4:1), 4% (v/v) horse serum) for 5 hours at 37ºC. Experiments were 
carried out 48 hours post transfection.   
For shRNA experiments shRNA harbouring adenovirus were generated using the BlockiT kit 
(Life Technologies). Two oligonucleotides specifically targeting rat Pkn1 mRNA were 
designed in silico using the BlockiT RNAi designer algorithm (Life Technologies): shRNA1 
(GGATAGTAAGACCAAGATTGA), shRNA2 (GGAAGACTTCTTGGACAATGA).  As a 
negative control, two oligomers encoding a scramble sequence predicted not to target any 
known mammalian gene were designed as described above: NC1 
(GGAATGGACAAGCAATAAGTT), NC2 (GCTATACTTCTACGACTATGC).   
Oligonucleotides were cloned into pADDESTPL for subsequent adenoviral generation 
according to the manufacturer’s instruction.  
2.6 Adenoviral Gene Transfer 




Adenoviral constructs in pADDESTPL were generated as described above. Adenovirus were 
generated according to the BlockiT Adenoviral kit (Life Technologies).  Briefly, linearized 
pacmid DNA was transfected in HEK293 cells using Lipofectamine 2000 (Life Technologies) 
and resulting adenovirus were isolated using repeated freeze-thaw cycles.  Adenoviral titre 
was determined using the AdEasy Viral Titre kit (Agilent Technologies).   NRVMs were 
infected 48 hours after isolation in maintenance media.  Media was replaced 24 hours after 
infection.      
2.7 Simulated Ischemia (sI) 
Sublethal SI was induced by treating NRVMs with a modified Krebs buffer containing (in mM): 
137 NaCl; 12 KCl; 0.49 MgCl2; 1.8 CaCl2; 4 HEPES supplemented with 10mM 2-
deoxyglucose; 20mM Na lactate; and 1 mM oxygen scavenger (sodium dithionite) pH 6.8. to 
simulate the extracellular milieu of myocardial ischemia as described previously3.  Briefly, 
cells in 6-well tissue culture plates were exposed to 1.0 mL per well SI buffer at 37.0ºC.  
Simulated reperfusion was achieved by removing the SI buffer and replacing with 
maintenance media (MM) for the indicated time. 
2.8 Gel electrophoresis and Western blotting 
Protein extracts were separated by SDS-PAGE using a mini-protean II apparatus (Biorad, 
UK) essentially as previously described 3, except that for resolution of phospho- and total-
PKN1 and PKN2, 6% gels were used (figures 1A; 3A; 3B). For experiments analysing 
immunoprecipitations and heart extracts for phospho- and total-phospholamban (PLB), pre-
cast 4-20% gradient gels (ThermoScientific, UK) were used (figures 7; 8; 9). For the analysis 
of heart extracts for phosphor- and total-MAPK/SAPK, 12.5% gels were used (figure 1B). 
Western blotting was performed as previously described 3 following electrophoretic transfer 
onto PVDF membranes (Hybond-P®,GE Healthcare, UK) using a mini-Protean II Transblot 
apparatus (Biorad, UK). Membranes were blocked in 2% (w/v) powdered milk (Marvel®) in 
PBS; 0,05% Tween 20 (PBST), incubated with primary antibodies for 3 hours at RT at 1:1000 
dilution in PBST; 0.1% milk (PBSTM), washed 3x 5mins in PBSTM, incubated with the 
appropriate HRP-conjugated secondary antibodies (DAKO, UK) for 1 hour at RT at 1:2500 
dilution in PBSTM, washed 3x 5 mins in PBSTM and developed with ECL enhanced 
chemiluminescence reagent (GE Healthcare, UK). Exceptions were anti-total PLB and anti-
SERCA2a which were used at 1:4000 and 1:5000 dilution, respectively. Where indicated 
(figure legends) phosphor-blots were stripped with 0.5M NaOH for 30 min at RT followed by 
several washes in ddH2O prior to re-probing with pan (total) kinase antibody. For PhosTag™ 
gel analysis of PKN1 phosphorylation, samples were run on 8% gels supplemented with 
PhosTag™ acrylamide (Wako Chemicals, Germany) and MnCl2 to a [final] 40M. Gels were 
electrophoresed at a constant 90V. 
2.9 Determination of NRVM Injury  
Cell injury following SI and reperfusion was determined by creatine phosphokinase (CPK) 
efflux (membrane damage) and methyl thiazoyltetrazolium (MTT) metabolism (cell viability) 
as described previously3.    NRVMs were exposed to 1 hour of SI then reperfused in 1.0 mL 




of MM.  2 hours after reperfusion, the media was collected and assessed for CPK activity 
using a commercially available kit (Abnova, Taiwan) according to the manufacturer’s 
instructions.  Fresh MM was applied to the NRVMs and allowed to reperfuse for a further 18 
hours.  Cell viability was measured using an MTT assay as previously described3.  Cells were 
washed in warm PBS and incubated with 0.5 mg/mL MTT in PBS for 30 mins at 37ºC.  The 
reaction was stopped by the addition of an equal volume of solubilisation solution (0.1N HCl, 
10% (v/v) Triton X-100 in isopropanol), and the absorbance of the blue formazan derivative 
read at 570 nm.    
2.10 Immunofluorescence experiments  
Cells were fixed in 4% paraformaldehyde, permeabilised with 0.2% (v/v) Triton X-100 and 
blocked with 2% (w/v) BSA in PBS. Cells were incubated with primary antibodies overnight 
at 4ºC. Cy3- or Cy5-coupled secondary antibodies were applied for 2 hours at room 
temperature.   Cells were mounted with VectaShield containing DAPI and visualized using 
Leica SP5 confocal microscope. For quantitation of PKN1 SR localisation, 16 bit confocal 
images were imported in to Wolfram Mathematica v11.0 (Champaign, IL) and were 
background subtracted using a 51 pixel radius Gaussian kernel. The images were then 
bandpass filtered at a frequency corresponding to the spacing of the SR and with a quality 
factor of 1 using the inbuilt "BandpassFilter" command. This filtered image was binarized to 
create a mask for SR resident protein and an inverted version for non-SR protein. These 
masks were then multiplied by the background subtracted images. The total intensity was 
then calculated from these images to give the total amount of protein (in arbitrary units) in 
both pools. The ratio of SR localised protein to total protein was then calculated. This analysis 
was performed blinded to genotype.      
2.11 Immuno-precipitation 
PKN1-FLAG was immunoprecipitated from NRVMs using ANTI-FLAG® M2 Affinity gel 
(Sigma-Aldrich) according to the manufacturer’s instruction.  Briefly, NRVMs were lysed in 
ice-cold Lysis Buffer (50 mM Tris HCl, pH7.4; 150 mM NaCl; 1 mM EDTA; 1% (v/v) TRITON 
X-100; cOmplete protease inhibitor cocktail tablet  (Roche)).  Lysates were centrifuged for 1 
min at 1000 xg at 4.0ºC to remove cell debris and then  incubated with the affinity gel for 2 
hours at 4.0ºC with gentle agitation.  After washing the beads in cold TBS, PKN1_FLAG was 
eluted by boiling in 2x sample buffer for 3 min.  20% (v/v) β-mercaptoethanol was added 
before SDS-PAGE analysis.  
2.12 Langendorff Perfused Murine Heart Preparation 
Age-matched 10-12 week old male PKN+/+ (WT) and PKN-/- (KO) littermate mice were 
anesthetized with pentobarbital sodium in combination with heparin (200 mg/kg and 200 
IU/kg, respectively, ip).  Hearts were rapidly excised and placed in cold (4.0ºC) K-H buffer 
(118.5 mM NaCl; 25.0 mM NaHCO3; 1.18 mM KH2P04; 1.19 mM MgSO4.7H20; 11 mM 
glucose; 1.04 mM CaCl2, pH 7.4)  , and the aorta was cannulated with a ‘’blunted’’ 21-gauge 
needle.  Hearts were then perfused with oxygenated (95% 02-5% CO2) K-H  buffer at 37.0ºC.  
Perfusion was in the non-recirculating Langendorff mode at a constant pressure equivalent 




to 80 mmHg, and were paced at 600 beats per minute (bpm).  Left ventricular developed 
pressure (LVDP) measurements were performed with a fluid-filled balloon inflated to give an 
end diastolic pressure of ~4-9 mmHg. Cardiac performance was further analysed by 
determination of pressure-volume relationships (PV loop analysis) as previously described in 
detail 26. For this study mice of different genotypes were randomised into the baseline or 
infarction groups. 
2.13 Infarct Size Measurement  
At the end of the protocol, hearts were perfused with 1% triphenyl tetrazolium chloride (TTC) 
in warm K-H buffer (Sigma, UK) for 3 min and immediately fixed in 4.0 % formaldehyde 
overnight at 4.0ºC.    Fixed hearts were rinsed in cold PBS, set in 4.0 % agarose and 
sectioned with a Vibratome™ 1000 plus (Products International Inc, USA) at thickness of 
0.75 m. Sections were scanned at 1200 dpi and the infarct area delineated with planimetry 
using Sigma Scan Pro software and surface area transformed to volume by multiplication 
with tissue depth.  The infarct size was expressed as the percentage of area at risk, defined 
as the sum of total ventricular area minus cavities. Analysis of infarct size by planimetry was 
performed blinded to genotype. 
2.14 Cell Fractionation 
NRVMs were harvested in cold Buffer A [10 mM HEPES, pH 7.4, 0.154 M KCl, 1 mM EDTA, 
20% (v/v) glycerol] and lysed by three 12s bursts of sonication on ice. Cell lysates were 
centrifuged at 1000g for 10 min at 4°C. The pellet (P1) was washed in Buffer A and was 
resuspended in 2x sample buffer.  The fraction was denoted as the ‘insoluble fraction’. The 
supernatant (S1) was centrifuged at 100,000g for 1 h at 4°C. The supernatant from this step 
(S2) was denoted ‘Cytosolic fraction’.  The pellet from the fast spin (P2) was washed three 
times in Buffer A and resuspended in the same buffer using a glass-glass homogenizer 
placed on ice.  This was denoted the ‘membrane fraction’.  The cytosolic and membrane 
fractions were prepared in 2x SDS-PAGE sample buffer.    All samples were stored at -20ºC 
until SDS PAGE analysis.  
2.15 Sample preparation from Langendorff perfused hearts 
At the end of the protocol, perfused hearts in Langendorff mode were harvested and 
immediately freeze clamped in liquid nitrogen.  Hearts were stored at -80ºC until analysis.   
Hearts were homogenized in  homogenization buffer (50 mM Tris HCl (pH7.4); 1 mM EGTA; 
1 mM EDTA; 1% (v/v) TRITON X-100; 0.1% (v/v) β-mercaptoethanol; 50 mM NaF; cOmplete 
protease inhibitor cocktail tablet  (Roche)) to a concentration of 100 mg/mL using a hand held 
homogenizer for 3 min on ice.   An equal volume of 2x loading buffer with 20% (v/v) β-
mercaptoethanol was added was and boiled for 5 mins at 95.0ºC.  Samples were stored at -
20.0ºC until further analysis. 
2.16 LC-MS/MS 




Gel bands were excised and pooled prior to digestion, extraction and analysis by mass 
spectrometry. LC-MS/MS was performed by Mr Steven Lynham, King’s College London 
Centre of Excellence for Mass Spectrometry (CEMS), Institute of Psychiatry, Denmark Hill. 
(i) Enzymatic Digestion 
In-gel reduction, alkylation and digestion with trypsin were performed prior to subsequent 
analysis by mass spectrometry. Cysteine residues were reduced with dithiothreitol and 
derivatised by treatment with iodoacetamide to form stable carbamidomethyl derivatives. 
Trypsin digestion was carried out overnight at room temperature after initial incubation at 
37oC for 2 hours. 
(ii) LC-MS/MS  
Peptides were extracted from the gel pieces by a series of acetonitrile and aqueous washes. 
The extract was pooled with the initial supernatant and lyophilised. Each sample was then 
resuspended in 10L of 50mM ammonium bicarbonate and analysed by LC/MS/MS. 
Chromatographic separations were performed using an EASY NanoLC system 
(ThermoFisherScientific, UK). Peptides were resolved by reversed phase chromatography 
on a 75 m C18 column using a three step linear gradient of acetonitrile in 0.1% formic acid. 
The gradient was delivered to elute the peptides at a flow rate of 300 nL/min over 180 min. 
The eluate was ionised by electrospray ionisation using an Orbitrap Velos Pro 
(ThermoFisherScientific, UK) operating under Xcalibur v2.2. The instrument was 
programmed to acquire in automated data-dependent switching mode, selecting precursor 
ions based on their intensity for sequencing by collision-induced fragmentation using a Top20 
CID method. The MS/MS analyses were conducted using collision energy profiles that were 
chosen based on the mass-to-charge ratio (m/z) and the charge state of the peptide. 
2.17 Statistical Analysis 
Statistical analysis was by Two-Way ANOVA with a Bonferroni post-hoc test; One Way 
ANOVA with a Newman-Keuls post-hoc test or unpaired T-test (GraphPad Prism 5®) where 
significance is expressed as *p<0.05, **p<0.01, ***p<0.001 versus control as appropriate to 
the experiment.  For confocal analysis of PKN1 co-localisation to the SR a nested ANOVA 
was performed using the RealStatistics™ add-in for MS Excel.





3.1 Characterisation of PKN1 null mice 
PKN1-/- mice show no expression of PKN1 and no compensatory changes or PKN2 or PKN3 
expression (supplementary figure S1 and 25). Firstly, we analysed cardiac hemodynamic and 
functional parameters in WT and PKN1 KO hearts perfused in Langendorff mode, both at 
baseline (supplemental figure 2A-C) and following ischemia and reperfusion (I/R) [figure 1A 
(i-iii)]. There were no differences in baseline hemodynamic parameters between WT and 
PKN1 KO hearts. Following 30 min global ischemia and 120 mins reperfusion, functional 
recovery (LVDP) was 33.6+6.1% (n=8) in WT hearts, whereas LVDP recovered significantly 
less, 17.7+3.9% (n=8) (p<0.05) in PKN1 KO hearts [figure 1A (i)]. There no significant 
difference in end diastolic pressure (EDP) [figure 1A (ii)] or coronary flow [figure 1A (iii)]. 
between genotypes. These results reflect increased injury and decreased functional recovery 
in PKN1 KO hearts following I/R. Comparison of the extent of ischemic injury (necrosis) was 
determined and the infarct size (IS) expressed as a percentage of the area at risk (AAR) 
following triphenyl tetrazolium chloride (TTC) staining. IS in the PKN1 KO hearts was 
45.1+2.9% compared to 25.5+0.8% in WT hearts (p<0.0001) [figure 1B (ii)]. Together, these 
results demonstrate that PKN1 KO hearts were significantly more susceptible to I/R injury 
compared to WT hearts. 
We next determined changes in PKN1 phosphorylation on Thr778, the activation loop PDK1-
dependent site, following ischemia and reperfusion in hearts from c57Bl/6 mice perfused in 
Langendorff mode. Hearts were analysed at 20 min of reperfusion following a 30 min ischemic 
episode since peak activation loop phosphorylation of canonical MAPKs/SAPKs (p42/p44-
MAPK, p46/p54-SAPK/JNK, p38-MAPK) were shown at this time point (supplementary figure 
S2). PKN1 Thr778 phosphorylation was relatively high at baseline and not different during I/R 
at this time point (figure 2A). We next compared the activation loop phosphorylation of the 
canonical MAPKs/SAPKs at this time point in PKN1 knockout (KO) compared to wild type 
(WT) littermate control hearts. In accordance with previous studies, I/R induced an increase 
in p46/p54-SAPK (JNK) and p38-MAPK phosphorylation compared to baseline. However, 
there were no differences between genotype in p38-MAPK or p46/p54-JNK phosphorylation 
following I/R. In contrast, p42/p44-MAPK (ERK1/2) Thr202/Tyr204 phosphorylation was 
significantly reduced at baseline and also following I/R (figure 2B and 2C). 
3.2 Molecular changes in PKN1 in isolated ventricular cardiomyocytes 
Having established that loss of PKN1 increased susceptibility to I/R injury in vivo, we next 
aimed to characterise the molecular changes in PKN1 using an established model of 
simulated ischemia/reperfusion (sI/R) in isolated primary neonatal rat ventricular 
cardiomyocytes (NRVM) 3. Canonical MAPK/SAPK phosphorylation patterns in NRVM in 
response to sI/R were consistent with those see during global ischemia and reperfusion in 
isolated hearts (Supplementary figure S3). Firstly we examined whether there are dynamic 
changes in endogenous PKN1 Thr778 phosphorylation during sI/R, given that basal Thr778 
phosphorylation was unchanged following 30 min I/20 min R in isolated hearts (figure 2A). 




Figure 3A shows that the basal activation state of endogenous PKN1 as determined by Thr778 
phosphorylation was relatively high in NRVM under these conditions. Thr778 phosphorylation 
was unchanged during sI until at least 30 min. However, following extended sI to 60 min, 
Thr778 phosphorylation was subsequently lost. This is consistent with a general loss of global 
kinase activity due to run-down of cellular ATP levels with extended ischemia times. Following 
loss of Thr778 phosphorylation after 60 min sI, Thr778 phosphorylation recovered during 
‘reperfusion’ (results not shown). The antibody used to detect endogenous Thr778 
phosphorylation also recognises the equivalent activation loop phosphorylation site, Thr816, 
in PKN2. PKN2 Thr816 phosphorylation showed parallel changes to PKN1 Thr778. 
To determine whether PKN1 stability or Thr774/778 phosphorylation was dependent on PKN1 
kinase activity itself, we introduced an active site mutation (K644R) into the human PKN1 
cDNA to render it kinase dead (KD-hPKN1-FLAG). NRVM were transduced with 
adenoviruses expressing WT- or KD-hPKN1 and subjected to sI. As shown in figure 3B Thr774 
phosphorylation of the transfected WT-hPKN1 was unaffected by sI up to 60 mins. 
Furthermore, Thr774 phosphorylation was also unaffected by the K644R mutation (figure 3C). 
Changes in phosphorylation of the PKN1 activation loop Thr774/778 reflect the upstream PDK1 
activity. However, it is also likely that changes in other phosphorylation sites on PKN1 may 
regulate PKN1 kinase activity and/or localisation during I/R. The role of other possible 
regulatory phosphorylation sites in PKN1 have not been characterised to date. To gain an 
insight into global changes in PKN1 phosphorylation we analysed samples from sI/R 
timecourses using PhosTag® gels in which protein mobility is retarded by adduction of the 
PhosTag® reagent to phosphorylated residues on the target protein, as detected using a 
pan-antibody on Western blots. The reduced mobility of PKN1 in cells treated with the 
phosphatase inhibitor calyculin A (positive control) showed that there are multiple 
phosphorylation sites on PKN1 which have the potential to be dynamically regulated by 
cellular kinase/phosphatase activity (figure 3D/E). Under control conditions PKN1 appeared 
as a doublet. During sI the accumulation of the lower, faster migrating band (designated -1) 
occurred between 20-60 min sI (figure 3D) indicative of net dephosphorylation of PKN1 during 
sI. Interestingly, rather than recovery of the basal phosphorylation state during early 
reperfusion, we observed further accumulation of the -1 species and the appearance of an 
additional faster migrating band (designated -2) between 5-15 min of recovery, indicative of 
further dephosphorylation (figure 3E). The basal state of PKN1 phosphorylation was then re-
established at later recovery times (20-60 min). These results demonstrate that whereas 
Thr778 phosphorylation is unchanged during sI and subsequent reperfusion, phosphorylation 
of other sites is very dynamic during I/R. 
3.3 Role of PKN1 in cellular injury 
In order to recapitulate the in vivo scenario whereby loss of PKN1 increased susceptibility to 
I/R injury, we knocked down PKN1 expression in NRVM using si RNA, then subjected the 
cells to sI/R and assessed the extent of cell injury/survival. Figure 4A shows that under 
optimal conditions using two different siRNA constructs, loss of PKN1 expression was >95% 
compared to a scrambled sequence negative control construct. Cells were subjected to 1 hr 
sI followed by 18 hr recovery in normal maintenance medium. sI/R times were optimised to 




result in approx. 50% cell death in control cells as determined using MTT bioreduction as an 
index of cell survival. Knockdown of PKN1 had no effect on the survival of cells under control 
conditions. However, loss of PKN1 following siRNA knockdown resulted in a significant 
further loss of cell viability following sI/R (figure 4B). Cell injury was assessed in parallel by 
measurement of creatine phosphokinase (CPK) release during the first 90 min of recovery 
from sI (figure 4C). PKN1 knockdown resulted in an approx. doubling of CPK release during 
early recovery from sI. These results demonstrate that in keeping with results obtained in 
PKN1 KO hearts, loss of PKN1 results in increased susceptibility of cardiomyocytes to sI/R 
injury. 
These results demonstrate that the baseline susceptibility of cardiomyocytes to I/R injury is 
dependent on the PKN1 level. To directly determine an overt protective role for PKN1 in sI/R 
injury, we overexpressed WT-hPKN1-FLAG or KD-hPKN1-FLAG using adenoviral-mediated 
transduction. Western blotting against the FLAG epitope showed successful and equivalent 
high level expression of both species (figure 4D). In vitro kinase assay of cell lysates following 
IP of WT- and KD-hPKN1-FLAG using an anti-FLAG antibody confirmed the absence of 
kinase activity in the KD-hPKN1 mutant (figure 4E). Interestingly, both WT and KD-hPKN1 
increased cell viability (figure 4F) and reduced cell injury (figure 4G) to an equivalent degree 
(approx. 30%). These results suggest that the kinase activity of PKN1 is not required for its 
protective function. 
3.4 Changes in PKN1 localisation during sI/R in ventricular cardiomyocytes 
We next sought to determine whether PKN1 intracellular localisation changes during sI/R and 
whether or not PKN1 kinase activity is required for PKN1 translocation. NRVMs were 
transduced with FLAG-tagged hPKN1 and confocal immunofluorescence microscopy was 
performed using an anti-FLAG or monoclonal anti-PKN1 antibody. Figure 5A shows that in 
control cells PKN1 had a diffuse punctate staining pattern with some overlap with staining for 
filamentous actin (FITC-phalloidin). Interestingly, following sI PKN1 relocalised to a striated 
pattern with a repeating large amplitude register of approximately 1.8m with alternating 
small amplitude register consistent with a sarcomeric/myofilament localisation (figure 5A, B). 
Furthermore, the redistribution of WT-hPKN1-FLAG and KD-hPKN1-FLAG was identical 
(figure 5B), suggesting that kinase activity is not required for this redistribution. 
To determine whether relocalisation of PKN1 corresponds to a sarcomeric redistribution, cells 
were co-stained for the myofilament markers myomesin (M-band) and -actinin (z-disc). The 
small amplitude PKN1 band overlapped with myomesin (figure 5C) and the large amplitude 
PKN1 band staining falls between the myomesin bands with an identical register, suggesting 
a myofilament localisation. There was also limited overlap with -actinin, suggesting partial 
Z-disc localisation. Because PKN1 staining showed a sarcomeric pattern which 
corresponded partially to A-band or M-band and Z-disc, we compared PKN1 to the 
sarcoplasmic reticulum (SR) marker SERCA2a. Under control conditions staining for 
SERCA2 showed a striated sarcomeric pattern with some perinuclear staining consistent with 
ER (figure 6A, top panels). Co-staining for PKN1 showed a very similar pattern (figure 6A, 
middle panels) and the merged images show a high degree of overlap (figure 6A, lower 




panels and figure 6B). Quantitative analysis of confocal images showed a significant increase 
in PKN1 SR localisation during sI (figure 6C). 
Because of differences in SR structure and function between neonatal and adult 
cardiomyocytes, we next examined the relationship between PKN1 and SERCA2a in isolated 
adult cardiomyocytes. The results shown in supplementary figure S4 confirm that PKN1 also 
shows a high degree of co-localisation with SERCA2 in adult cardiomyocytes with a fully 
mature and functional SR under conditions of sI. However, in control adult cardiomyocytes 
PKN1 showed some overlap with SERCA2a but only displayed the large amplitude register 
and was irregular. Following sI the pattern of PKN1 distribution was much sharper and 
showed the alternating large/small amplitude striated register as observed in NRVM following 
sI. This redistribution of PKN1 during sI in adult cardiomyocytes is represented schematically 
in supplementary figure S5. Interestingly, the resident ER protein reticulon 4 (NogoA) also 
co-localised with PKN1 under these conditions. Supplementary figure S6 shows that in 
sections of normal adult mouse hearts PKN1 immunofluorescence has a striated pattern 
coincident with phalloidin staining of actin at the I-band. However, this would also be adjacent 
to SERCA2 at the SR (see also supplementary figure S5). Taken together, these results show 
that PKN1 localisation overlaps with SERCA2 at the SR and that this localisation is enhanced 
during sI, suggesting a role for PKN1 in regulating SR function during ischemia. 
3.5 Interaction of PKN1 with ER/SR-associated proteins 
We reasoned that PKN1 relocalisation to SR during ischemia may be related to its interaction 
with other resident SR/ER proteins which are linked to its protective function. Therefore, to 
gain further insights into possible interacting partners, NRVMs were transduced with 
adenoviruses expressing hPKN1-FLAG and treated with sI for 30 min. hPKN1 was harvested 
by immunoprecipitation using an anti-FLAG Ab and candidate binding partners were 
identified by mass spectrophotometric analysis. Using this approach PKN1 was found to be 
associated with several resident ER/SR proteins only during sI. These included reticulon 4 
(Nogo A), calreticulin, reticulocalbins 1 and 2 (RCN1 and 2), as well as 14-3-3 and the E3 
ubiquitin ligase NEDD4 (supplementary table T1). In addition, PKN1 associated with Ca2+-
calmodulin-dependent kinase 2 delta (CamKII) which is a regulator of SR Ca2+ loading and 
release via SERCA2 and the ryanodine receptor (RyR2). Binding to 14-3-3 was confirmed 
in cell lysates only following sI (supplementary figure S7). 
In order to explore these interactions further we exposed cells to sI/R, fractionated them 
into soluble and particulate (membrane) fractions and probed the fractions for putative 
partners and compartmental markers. Figure 7A shows that PKN1 levels increased in the 
particulate fraction in parallel with a marked redistribution of CamKIIand NEDD4. Strict 
partitioning of Na+/K+ ATPase (NKA)  subunit and SERCA2 to the particulate fraction and 
Hsp90 to the soluble fraction demonstrate the fidelity of the fractions and also that the 
particulate fraction contains both sarcolemmal and SR membranes. 
We next determined whether during sI, PKN1 affects the phosphorylation of CamKIIand its 
downstream SR target phospholamban (PLB), an endogenous regulator of SERCA2 activity. 




Endogenous PKN1 expression was either left intact or knocked down using siRNA in NRVMs 
prior to exposure to sI for various times. The results show that under control conditions and 
during sI, loss of PKN caused a dramatic increase in CamKIIThr287 phosphorylation 
indicative of kinase activation (figure 7B). Furthermore, there was a marked increase in 
CamKII-dependent PLB Thr17 phosphorylation at 2-5 min. By 10 min sI PLB Thr17 
phoshorylation returned to baseline. These results indicate that loss of PKN1 results in a 
marked activation of CamKII and downstream PLB Thr17 phosphorylation. 
We then compared the effect of siRNA knockdown of PKN1 to overexpression of PKN1 on 
CamKII activation and PLB phosphorylation. PLB phosphorylation increased during 2-5 min 
sI only following PKN1 knockdown (figure 8A), whereas in the presence of overexpressed 
WT-hPKN1 PLB phosphorylation was absent (figure 8B). There was also no change in PLB 
phosphorylation following overexpression of KD-hPKN1 suggesting that inhibition of 
CamKII-dependent PLB phosphorylation is independent of PKN1 kinase activity. 
To investigate the effect of PKN1 knockdown on CamKII and NEDD4 redistribution cells 
were exposed to sI following PKN1 siRNA treatment and fractionated. NEDD4 localisation to 
the particulate (membrane) fraction was increased by PKN1 knockdown. CamKII 
redistribution to the membrane fraction was also increased upon loss of PKN1 (figure 8C). 
Input material is shown in figure 8D. 
3.6 Effect of PKN1 loss on SR Ca2+ handling proteins in vivo. 
We next investigated whether the loss of PKN1 resulted in altered SR protein levels or 
phosphorylation in vivo. Hearts were isolated from WT and PKN1 KO mice at baseline. Figure 
9 shows that basal phosphorylation of PLB Thr17 was greatly increased in PKN1 KO hearts 
compared to WT whereas levels of total PLB were unchanged. The increase in PLB Thr17 
phosphorylation in PKN1 KO hearts was equivalent to the level of phosphorylation observed 
in c57Bl/6 hearts during I/R. Interestingly, levels of SERCA2a were also increased in PKN1 
KO hearts. Since PLB phosphorylation de-represses SERCA2 activity, together these results 
suggest a compensatory enhancement of SR Ca2+ uptake in PKN1 KO hearts. Levels of 
CamKII phosphorylation and expression were unchanged at baseline. Levels of the 
Na+/Ca2+ exchanger (NCX) were also unaffected. Furthermore, increased expression of the 
junctional membrane complex (JMC) structural component Junctophilin-2 (Jph2) was also 
observed (Figure 9). 
3.7 Functional changes in PKN1 KO hearts. 
These molecular changes in SR Ca2+ regulatory proteins would be expected to result in 
altered SR Ca2+ handling and thus be reflected by changes in cardiac contractile 
performance. In order to test this possibility, WT and PKN1 KO hearts were subjected to 
echocardiographic and pressure-volume (PV) loop analysis using an admittance catheter 
inserted into the left ventricle. The results shown in supplementary figure S8 show that PKN1 
KO hearts were essentially compensated at baseline and had normal ejection fraction, 
systolic and diastolic volumes and pre-load-independent relaxation constant (Tau). Normal 




systolic and diastolic volumes and anterior wall thickness were also confirmed by 
echocardiographic analysis (results not shown). However, posterior wall thickness at diastole 
(PWTD) was significantly higher in KO hearts (Figure 10A). Furthermore, PKN1 KO hearts 
had a trend towards altered functional characteristics compared to wild type hearts under 
conditions of decreased preload (IVC occlusion), including decreased end systolic pressure-
volume relationship (ESPVR), increased end diastolic pressure-volume relationship 
(EDPVR) and decreased preload recruitable stroke work (PRSW), although these changes 
did not reach statistical significance (Supplemental figure S8). However, more detailed 
analysis of the beat-to-beat relationship between systolic pressure (SP), the maximal rate of 
systolic pressure development (dP/dT max) and the maximal rate of relaxation (dP/dT min) 
normalised to the end diastolic pressure (EDP) of the preceding cycle showed a significant 
decrease in systolic P and also a decrease in the maximal rate of systolic P generation and 
the rate of relaxation in KO hearts (Figure 10B). This is suggestive of an underlying systolic 
and diastolic dysfunction with preserved ejection fraction (EF: supplementary figure S8) 
which relates to an altered Frank-Starling response. Representative scatter plots of SP 
versus EDP for an individual WT and KO mouse are shown in Figure 10C. Intra-beat 
relationships for EDP versus SP, EDP versus rate of contraction (dP/dT max) and EDP 
versus rate of relaxation (dP/dT min) were determined. The intra-beat relationships between 
EDP and SP, EDP and dP/dT max (+dP/dT) and EDP and dP/dT min (-dP/dT) determined 
as the coefficient (R2) were significantly decreased in KO hearts (figure 10D) indicating that 
coupling between EDP and contractile function was significantly impaired in PKN1 KO hearts. 
4. Discussion 
The results obtained in this study show that loss of PKN1 increases susceptibility to 
ischemia/reperfusion (I/R) injury both in the intact heart and in isolated, cultured 
cardiomyocytes, suggesting a cell-autonomous, intrinsic basal cardioprotective role for PKN1 
in cardiomyocytes and as previously suggested 24. Loss of PKN1 was associated with 
increased activity of CamKII and phosphorylation of its downstream substrate PLB on Thr17 
as well as upregulation of the sarcoplasmic reticulum ATPase SERCA2. These results 
suggest that PKN1 has a scaffold role which may function to prevent or limit CamKII access 
to specific substrates such as PLB during ischemia. Translocation of PKN1 and association 
with CamKII at the SR during sI correlates with PKN1-dependent cardiomyocyte 
cytoprotection. Since PKN1-dependent cardioprotection is intrinsic to cardiomyocytes, the 
model of global ischemia used in this study is consistent with results from in vivo studies 24. 
In freshly isolated spontaneously contracting NRVM the SR is reportedly less well developed 
and excitation contraction coupling is mainly dependent on extrinsic Ca2+ entry via L-type 
voltage-gated Ca2+ channels. However, after several days in culture the SR in NRVM was 
distinct and well developed and involved in Ca2+ sequestration and release 25, 27, 28. The 
cellular distribution of PKN1 was similar in NRVMs and adult cardiomyocytes and in both 
cases the tight alternating large/small amplitude double striated register only appeared under 
(simulated) ischaemic conditions. Irrespective of developmental differences in SR 
structure/function, loss of PKN1 was associated with an increase in PLB Thr17 
phosphorylation both in adult hearts and NRVM. Therefore, taken together these results 




suggest that the presence of PKN1 at the SR itself inhibits CamKII-dependent PLB 
phosphorylation. 
Dysregulation of SR Ca2+ handling during reperfusion following ischemia correlates with 
CamKII activity 29-32 and CamkII has an established role in promoting I/R injury since 
inhibition of CamKII limits infarct size 33-35. Cytosolic Ca2+ overload during I/R is associated 
with cytosolic Ca2+ oscillations which occur prior to cardiomyocyte cell death due to 
mitochondrial Ca2+ overload and MTP pore opening 36. These Ca2+ oscillations are due to 
increased SR Ca2+ loading via increased SERCA2 activity (ie following PLB Ser16/Thr17 
phosphorylation) coupled with Ca2+ leak via the SR Ca2+ release channel (ryanodine receptor: 
RyR2). RyR2 destabilisation or increased open probability during I/R has been attributed to 
a number of mechanisms including Ser2814 phosphorylation by CamKII itself, loss of 
calstabin1 (FKBP12.6) binding and Ca2+/calpain-dependent proteolytic degradation of RyR2 
37. We did not observed any direct evidence of RyR Ser2814 phosphorylation (results not 
shown). However, it is also possible that destabilisation of the T-tubule/SR junctional 
membrane complex (JMC) may occur due to Ca2+-dependent degradation of other key 
structural proteins such as junctophilin-2 (Jph2) which stabilises the JMC and is degraded 
following I/R 38, 39. We observed increased expression of Jph2 in PKN1 KO hearts (figure 9) 
suggesting turnover and/or remodelling of JMC components. Although speculative without 
further detailed analysis of SR function, these results suggest that coupling of SR Ca2+ 
handling is destabilised in PKN1 KO hearts which could increase Ca2+ overload during I/R. 
The main events involved in cardiomyocyte cytosolic Ca2+ overload following I/R are 
summarised schematically in supplementary figure S9. 
PLB Thr17 phosphorylation relieves its inhibitory action on SERCA2, thus increasing SERCA2 
activity. Coupled with increased SERCA2 levels in PKN1 KO hearts this would be expected 
to be associated with increased SR Ca2+ loading and faster relaxation or recovery of 
relaxation following I/R 40. This in itself may be protective in I/R provided that it is not 
accompanied by increased SR leak. Increased SR Ca2+ loading would be reflected by 
increased myocardial contractility as indicated by increased dP/dTmax and ESPVR. This was 
not observed in PKN1 KO hearts. In fact PKN1 KO hearts had the same average dP/dTmax 
and ejection fraction as WT hearts. However, beat-to-beat systolic P and dP/dT max 
normalised to EDP were significantly decreased in KO hearts as was dP/dT min, whereas 
diastolic posterior wall thickness was increased, suggesting increased diastolic stiffness and 
decreased systolic function relative to changes in EDP which may be due to increased resting 
cytosolic Ca2+. Therefore, it is likely that stroke volume (SV) and systolic P (SP) are 
compensated in KO hearts at the expense of elevated EDP. Interestingly, the phenotype of 
the PKN1 KO mice is strikingly similar to protein kinase G I (PKGI) Cys42Ser knock-in mice 
which centres on oxidation-dependent alterations in PLB (Ser16) phosphorylation and the 
coupling of EDP changes to contractile function41. However, since EDP was not significantly 
different during reperfusion following ischaemia [figure 1A (ii)], increased SR Ca2+ loading 
may mitigate against increased EDP during reperfusion. 




Whilst these changes could reflect defective SR function and increased cytosolic diastolic 
Ca2+, it could also be postulated based on the increased SERCA2a levels and PLB Thr17 
phosphorylation that higher SR Ca2+ load and PLB Thr17 phosphorylation may be expected 
increase the frequency and amplitude of cytosolic Ca2+ oscillations following IR injury 36 and 
spontaneous SR Ca2+ release (Ca2+ spark) frequency at baseline thus exacerbating I/R injury. 
This is supported since delayed PLB phosphorylation contributes to the protection afforded 
by ischemic post-conditioning 42 and although PLB ablation rescues SR Ca2+ loading, it 
exacerbates injury 30. Alternatively, the elevation of SERCA2a and Jph2 expression and PLB 
Thr17 phosphorylation may be an abortive adaptive response to dysregulated SR Ca2+ 
handling in PKN1 KO hearts (ie SR Ca2+ leak). These possibilities need to be explored further. 
PKN1 Thr774 phosphorylation in the activation loop by PDK1 has been shown to be essential 
for PKN1 catalytic activity and stability 14-16. Although modest Thr778 phosphorylation was 
observed during I/R in intact hearts and sI/R in isolated, cultured NRVM, Thr774 
phosphorylation of ectopically expressed kinase dead (KD) PKN1 was also observed. 
Furthermore, the kinase activity of PKN1 was not required for its protective effect because 
ectopic expression of KD(K644R)-hPKN1 was as protective as wild type hPKN1 against sI/R 
in NRVM. Irrespective of Thr774 phosphorylation, these results suggest the protective role of 
PKN1 is due to a scaffold/assembly function not directly dependent on downstream substrate 
phosphorylation by PKN1. 
Another recent example of a kinase-independent endogenous cardioprotective function has 
been described for PI3K 43 which, like PKN1 in this instance, behaves as a pseudokinase. 
Although PI3K is reported to be responsible for Reperfusion Injury Salvage kinase (RISK) 
pathway (Akt/ERK1/2) activation downstream of GPCR activation during reperfusion 5, 
intriguingly a kinase dead PI3KKD/KD knock-in onto the PI3K KO background rescued the 
PI3K KO phenotype. Furthermore, PI3K KO was associated with decreased ERK1/2 
activation and increased basal PLB Ser16 phosphorylation which is the adjacent cAMP-
dependent (PKA) site 43. CamKII Thr17 phosphorylation wasn’t determined in their study, but 
is also likely to be increased. Intriguingly p42/p44-MAPK (ERK1/2) activation was also 
decreased in PKN1 KO hearts at baseline and following I/R and may contribute to the loss of 
cardioprotection. However, this possibility needs to explored directly. Therefore, the PI3K 
KO and PKN1 KO mice have strikingly similar phenotypes. Also, RCN1 has been shown to 
act as an inhibitor of the activation of the B-Raf-MEK-ERK pathway in cardiomyocytes via 
interaction with B-Raf 44. The inhibition of B-Raf by RCN1 is Ca2+-dependent. Therefore, 
because we observed an interaction between PKN1 and RCN1, PKN1 could activate ERK 
signalling during I/R by interaction with and inhibition of RCN1 which impinges on Ca2+ 
regulation at the level of PLB phosphorylation at the SR. This would be consistent with a loss 
of PKN1 resulting in reduced ERK activation. 
Analysis of global PKN1 phosphorylation (ie on sites other than Thr778) during sI/R using gels 
containing PhosTag™ reagent showed a net dephosphorylation of PKN1. This was confirmed 
by mass spectrometry (results not shown) with a loss of phosphorylation on 9 and a gain of 
phosphorylation on 6 residues (out of 20) resulting in a net loss of 3. These results show that 




PKN1 phosphorylation is highly dynamic during sI/R. The roles of sites other than Thr774/778 
are not known in detail. However, sites within the N-terminal regulatory domain and linker 
region may be involved in PKN1 localisation 17. Also, a site or sites in the C-terminal kinase 
domain may be required for PKN1 localisation to a late endosomal compartment 18 since 
truncated PKN1 consisting of only the regulatory domain did not localise to this compartment. 
However, a kinase dead PKN1 mutant localised in response to hyperosmotic stress as for 
wild type, but accumulated to high levels, suggesting that PKN1 kinase activity is required for 
exit from this compartment 18. Further detailed analysis will be required to determine the role 
of additional phosphorylation sites in PKN1. In this study we have not specifically addressed 
the role of small GTPases (Rho/Rac) in PKN1 protective function. However, given that kinase 
activity does not appear to be important, it seems unlikely that the Rho/Rac-PDK1-PKN1 axis 
plays a prominent role. However this cannot be entirely excluded because the KD(K644R)-
hPKN1 mutant was still phosphorylated on Thr774 by upstream signals. 
PKN1 kinase activity not playing a facilitative or essential role in protection is somewhat 
divergent from the findings of Takagi et al 24. Whilst these authors demonstrated that 
cardiomyocyte-specific transgenic overexpression of constitutively active PKN1 was 
protective (as we found for wild type PKN1), transgenic overexpression of a dominant 
negative, kinase dead K644D mutant exacerbated I/R injury, rather than also protecting. K644 
is a conserved lysine in the ATP binding pocket and is essential for ATP binding and activity. 
K644R substitution is a classic strategy for generating kinase-dead mutants and maintains the 
overall size and charge distribution in the ATP binding pocket and is therefore assumed not 
to have other effects on structure, whereas the introduction of an aspartate (ie as in K644D) 
introduces a negative charge in place of a positive charge. This may have additional effects 
on structure or accessory protein/substrate binding etc. In our hands   K644R-PKN1 is clearly 
not dominant negative with respect to the protective function of PKN1. 
Mass spectrophotometric analysis of PKN1 immunoprecipitates following sI (30 min) 
demonstrated PKN1 association with several sarco-endoplasmic reticulum proteins including 
reticulon 4 (NogoA), calreticulin, reticulocalbin 1 (RCN1) and reticulocalbin 2 (RCN2) 
consistent with translocation to SR membranes. Interestingly, PKN1 also showed association 
with 14-3-3 and the E3 ubiquitin ligase NEDD4 (supplementary table T1) as well as CamKII. 
Cell fractionation studies confirmed that during sI PKN1 co-localised to the membrane 
fraction with CamkII and NEDD4, whereas 14-3-3 did not translocate (figure 8A). Following 
siRNA knockdown of PKN1 translocation of NEDD4 and CamKII were increased (figure 9C). 
This correlates with increased CamKII activity and PLB Thr17 phosphorylation under the 
same conditions (figure 7B). Interestingly, overexpression of WT- or KD-hPKN1 inhibited 
Thr17 phosphorylation without affecting CamKII Thr287 phosphorylation. This suggests that 
the predominant effect of PKN1 is to prevent CamKII-dependent PLB Thr17 phosphorylation 
rather than upstream CamKII phosphorylation itself. Since there is no global inhibition of 
CamKII (Thr287 phosphorylation), this is likely to be a localised effect at the SR membrane 
and may be a function of PKN1-dependent release of CamKII from the membrane. The role 
of PKN1 interaction with NEDD4 is unknown. However, Takagi et al 24 attributed PKN1 
protective function to facilitation of ubiquitin-proteasomal protein degradation. Despite this, 




we found no effect of proteasome inhibitors on the protective effect of PKN1 in 
cardiomyocytes (result not shown). Interaction of PKN1 with 14-3-3 in heart has been shown 
previously, where PKN1 is recruited to a large signalling complex by A-kinase anchoring 
protein AKAP-Lbc, recruiting and activating p38-MAPK. The complex is negatively 
regulated by 14-3-3 45, 46. This may be relevant given the known role of p38-MAPK in 
ischaemic injury, however, we found no effect of PKN1 knockout or knockdown on p38-
MAPK activation. 
In conclusion, PKN1 is shown to provide a basal cardioprotective function in the face of I/R 
injury. This protection is intrinsic to cardiomyocytes and involves attenuation of CamKII-
dependent phosphorylation events at the SR and possible stabilisation of the junctional 
membrane complex and thus SR Ca2+ uptake/release mechanisms and susceptibility to Ca2+ 
overload at reperfusion. 
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Figure 1:  Ischemia-Reperfusion Injury (Infarct size) is Increased in PKN1 Knockout hearts. 
Panel A: Haemodynamics in WT and PKN1 KO Hearts. Hearts were stabilised during 30 
minutes aerobic perfusion followed by 30 minutes global ischemia followed by 120 minutes 
reperfusion.  (i-iii): Haemodynamic parameters of isolated buffer-perfused hearts from 
matched littermate wild type (WT) and PKN1 knockout (KO). Values are presented as mean 
± SEM (n=8) for left ventricular developed pressure (LVDP), end diastolic pressure (EDP) 
and coronary flow (CF) recorded following 30 minutes stabilisation, 30 minutes global 
ischemia and 120 minutes reperfusion. LVDP was significantly reduced in the PKN1 KO 
hearts.  Statistical analysis was by Two-Way ANOVA with a Bonferroni post-hoc test, where 
significance is expressed as *p<0.05 versus WT. Panel B: (i): Representative images 
showing triphenyl tetrazolium chloride (TTC) staining of individual WT and PKN1 KO heart 
slices. Viable tissue is stained red and non-viable (necrotic) tissue appears white. (ii): Infarct 
volume as a percentage of area at risk (total heart volume) in age matched male littermate 
WT and PKN1 KO hearts subjected to 30 minutes global ischemia and 2 hours reperfusion. 
Results are expressed as mean + SEM (n=8). Statistical analysis was by One Way ANOVA 
with a Newman-Keuls post-hoc test, where ***p<0.001. 
Figure 2: PKN1 Thr778 Phosphorylation is Unchanged During Ischemia-reperfusion, but 
p42/p44-MAPK Phosphorylation is Reduced in PKN1 Knockout Hearts. Panel A: Wild type 
c57BL/6 mouse hearts were perfused in Langendorff mode and were subjected to 30 minutes 
global ischaemia and 20 minutes reperfusion. Hearts were harvested after 30 minutes of 
baseline perfusion or 30 minutes SI+20 minutes reperfusion by freeze-clamping followed by 
homogenisation and processing for SDS-PAGE and Western immunoblotting as described 
in the methods section. PKN1 activation loop phosphorylation (Thr778) was assessed by 
probing blots with anti-phospho-PKN1/2 (Thr774/Thr816) or anti-total PKN1 antibody. Total 
GAPDH was used as an additional control for loading. Phospho-PKN was quantitated by 
densitometry and normalised to total PKN and compared using a two-tailed unpaired T-test 
(n=3 individual hearts). Panel B: Matched littermate wild type (WT) and PKN1 knockout (KO) 
mouse hearts were perfused in Langendorff mode and subjected to 30 minutes global 
ischaemia followed by 20 minutes reperfusion.  Hearts were harvested and processed as 
above and MAPK and SAPK activation was assessed using antibodies recognizing dually 
phosphorylated p46/p54-SAPK (JNK), p38-MAPK and p42/p44-MAPK (ERK1/2) (upper 
panels) or the corresponding total protein (lower panels).  Panel C: Phospho-p42/p44-
MAPKs (P-ERK1/2) were quantitated by densitometry and normalised to total p42/p44-
MAPKs (T-ERK1/2) and compared using a two-tailed unpaired T-test (n=3 individual hearts). 
Each sample represents a different lysate prepared from individual hearts exposed 
independently to ischemia/reperfusion. Lysates from NRVMs treated with 50nM calyculin A 
(CLA) were used as a positive control for phospho-p42/44-MAPK, phospho-p46/p54-SAPK 
(JNK) and phospho-p38-MAPK. 
Figure 3: Thr774/778 Phosphorylation of PKN1 is Unchanged but Net Dephosphorylation 
Occurs on Other Sites During Simulated Ischemia/Reperfusion (sI/R) in Isolated 
Cardiomyocytes.  Panel A: NRVMs were treated with SI for up to 1 hour and harvested at 




the indicated times in 2x sample buffer. Phosphorylation of endogenous PKN1 was analysed 
by Western immunoblotting and probed with antibodies against phospho-PKN1 (Thr778) or 
total PKN1. Panel B: NRVMs were transfected with wild type- (WT) hPKN1-FLAG, treated 
with SI for up to 60 mins and harvested at the indicated times.  Samples were analysed by 
Western immunolotting to determine hPKN1 Thr774 phosphorylation and compared to levels 
of total PKN1 (T-hPKN1). Phospho blots were stripped and re-probed with anti-total PKN1. 
Panel C: NRVMs were transfected with kinase dead (KD:K644R)-hPKN1-FLAG, treated with 
SI for up to 60 mins and harvested at the indicated times.  Samples were analysed by 
Western immunolotting to determine hPKN1 Thr774 phosphorylation and compared to levels 
of total PKN1 (T-hPKN1). Phospho blots were stripped and re-probed with anti-total PKN1. 
Panel D: NRVMs were treated with SI for up to 1 hour and harvested as indicated in 2x 
sample buffer and analysed by PhosTag® SDS-PAGE followed by western immunoblotting 
as described in the materials and methods.  Immunoblots were probed with monoclonal 
antibody against total PKN1.  Panel E: NRVMs were treated with SI for 1 hour, ‘reperfused’ 
and harvested at the indicated times of ‘reperfusion’ and analysed by PhosTag® SDS-PAGE 
followed by Western immunoblotting. Immunoblots were probed with monoclonal antibody 
against total PKN1 as for panel A.  For all panels representative images are shown for one 
of three independent experiments. In each case NRVMs were treated with 50nM CLA as a 
positive control for maximal PKN1 phosphorylation. 
Figure 4: PKN1 is Protective Against Simulated Ischaemia/Reperfusion in Cardiomyocytes. 
NRVMs in which PKN1 was either silenced by siRNA treatment (Panels A-C) or 
overexpressed by adenoviral infection (WT-hPKN1-FLAG or KD-hPKN1-FLAG) (Panels D-
G) were exposed to 1 hour SI followed by 18 hrs of ‘reperfusion’.  Panel A: The efficacy of 
siRNA knockdown of PKN1 as analysed by western blot. Panel D: The efficacy of 
overexpression of FLAG-tagged wild type (WT) and kinase dead (KD) PKN1 as assessed by 
western blot using an anti-FLAG antibody. Panel E: Cells were transfected with WT- or KD-
hPKN1-FLAG and treated with 0.5M sorbitol for 30 min to activate PKN1. Cell lysates were 
prepared and IPd with anti-FLAG. Cell lysates were prepared and in vitro kinase assays 
performed using ATPS showing kinase activity of WT-hPKN-FLAG but not KD-hPKN1-FLAG 
towards a myelin basic protein (MBP) substrate. An anti-phosphothioate antibody was used 
for detection of MBP phosphorylation following Western blotting. Panels B and F: Cell 
viability was assessed by the conversion of MTT as described in the materials and methods 
section Results represent mean +/- S.E.M from 4 individual experiments in which each group 
was tested in triplicate.   Values from the control group were set as 1 and test groups were 
normalized to this.  Statistical significance of differences compared with SI/R:  *p<0.05, 
**p<0.01, ***p<0.001.  Cell injury was assessed by the activity of CPK as described in the 
materials and methods section (Panels C and G).  Results represent mean +/- S.E.M from 4 
individual experiments in which each group was tested in triplicate.   Values from the control 
group were set as 1 and test groups were normalized to this.  Statistical significance of 
differences compared with SI/R:  *p<0.05, **p<0.01, ***p<0.001 using One-Way ANOVA with 
a Newman-Keuls post-hoc test. 




Figure 5: Confocal Immunofluorescence Analysis of PKN1 Shows a Striated Redistribution 
During Simulated Ischaemia. Panel A: Translocation of PKN1 during SI. NRVMs infected 
with adenovirus expressing wild type (WT)-PKN1-FLAG and were either untreated (control) 
or subjected to 30 min SI prior to fixation. Slides were stained with mouse monoclonal anti-
PKN1 antibody (green) and counterstained with FITC-conjugated phalloidin (red) to visualise 
filamentous (F)-actin and with DAPI (blue) to visualise nuclei. Slides were analysed by 
confocal microscopy in the separate green, red and blue channels and a merged image is 
shown for the overlay of the individual images. Panel B: The localisation of WT-PKN1-FLAG 
and KD-PKN1-FLAG was compared during SI. NRVMs were infected with adenoviruses 
expressing WT-PKN1-FLAG (WT) or KD-PKN1-FLAG (KD) and treated with SI for 30 minutes 
prior to fixing and mounting.  Slides were stained with mouse monoclonal anti-PKN1 antibody 
(green) and counterstained with phalloidin (red). Panel C: NRVMs infected with adenovirus 
expressing wild type (WT)-PKN1-FLAG and were subjected to 30 min SI prior to fixation. 
Slides were stained with rabbit polyclonal anti-FLAG antibody (red) and counterstained with 
mouse monoclonal anti-myomesin antibody (green) or mouse monoclonal anti--actinin 
antibody (green), to visualise the M-band and Z-discs, respectively and with DAPI (blue) to 
visualise nuclei. Slides were analysed by confocal microscopy in the separate green, red and 
blue channels and a merged image is shown for the overlay of the individual images. Scale 
bar equals 10m. 
Figure 6: Confocal Immunofluorescence Analysis of PKN1 Shows a Sarcoplasmic Reticulum 
Localisation During simulated Ischaemia. Panel A: The co-localisation of PKN1 and Serca2a 
in NRVMs was compared during SI. NRVMs were infected with adenovirus expressing WT-
PKN1-FLAG and were either untreated (control) or subjected to 30 min SI prior to fixation 
and slide mounting. Slides were stained with mouse monoclonal anti-PKN1 antibody (green) 
and counterstained with Serca2a antibody to stain the SR membrane (red) and DAPI (blue). 
Slides were analysed by confocal microscopy in the separate green, red and blue channels 
and a merged image is shown for the overlay of the individual images. Scale bar is 10m. 
Panel B: The coincidence of PKN1 and SERCA2 localisation was determined during 
simulated ischemia. Confocal images representing  PKN1 in NRVMs under control conditions  
(i) and after 30’ SI (ii). The line charts (right panels) show the intensity plots of the Cy3 (PKN1) 
signal over the regions shown by a white line on the images. The distance between two major 
peaks and a major peak and minor peak are illustrated in the right panel. In (iii) the line chart 
shows the intensity plots of the Cy3 (PKN1) and Cy5 (SERCA2a) signals over the region 
shown by a white line on the merged image. In all cases experiments were repeated four 
times and >10 fields analysed per treatment. Panel C: Quantitation of PKN1 and SERCA2 
co-localisation. Panels (i) and (ii) show the masks generated for calculation of total and 
SERCA2 coincident PKN1. Panel (iii) shows quantitation of the fraction of SR coincident 
PKN1 normalised to total (cyto) cellular distributed PKN1 where *p<0.05 versus control (n=9 
per group) using a nested ANOVA with 3 batches of cells each in triplicate for each group. 
Figure 7: Association of PKN1 with Sarco-Endoplasmic Reticulum Binding Partners 
Correlates with CamKII and Phospholamban Thr17 Phosphorylation During Simulated 
Ischaemia. Panel A: NRVM were either untreated or subjected to sI and fractionated into 




soluble and membrane fractions. Fractions were subjected to SDS-PAGE and Western 
blotting and probed for PKN1 and its binding partners CamKII, 14-3-3 and NEDD4 or 
compartmental markers Na/K-ATPase (sarcolemmal membrane), Hsp90 (cytosol) and 
SERCA2a (SR membrane). Panel B: NRVM in which PKN1 was knocked down using siRNA 
were compared to control cells at different times of simulated ischemia (sI) and analysed for 
phosphorylation of CamKII (Thr287) or phospholamban (PLB: Thr17). For all panels 
representative images are shown for one of three independent experiments. Panel C: 
Quantitation of PKN1, phospho-CamKII (Thr287) and phosphor-PLB (Thr17) at 5 min of sI 
following treatment with negative control (NC) siRNA or PKN1 siRNA. Phosphor-CamKII 
and phospho-PLB were normalised to total CamKII and total PLB, respectively.  *P<0.05 or 
**p<0.001 (n=3) unpaired students T-test. 
Figure 8: CamKII and Phospholamban Thr17 Phosphorylation Are increased Following 
Knockdown of PKN1. Panel A: NRVM in which PKN1 was either knocked down using siRNA 
or overexpressed (Flag-PKN1) were compared to control cells at 2 min or 5 min of simulated 
ischemia (sI) and analysed for phosphorylation of CamKII (Thr287) or phospholamban (PLB: 
Thr17). Panel B: NRVM overexpression of wild type (WT) or kinase dead K644R (KD) PKN1 
were compared at 5 min of simulated ischemia (sI) and analysed for phosphorylation of 
CamKII (Thr287) or phospholamban (PLB: Thr17). Panel C: NRVM in which PKN1 was 
knocked down using siRNA were treated with sI/R and fractionated into soluble and 
membrane and then analysed for binding partners CamKII, 14-3-3 and NEDD4 or 
compartmental markers Na/K-ATPase (sarcolemmal membrane), Hsp90 (cytosol) and 
SERCA2a (SR membrane). Panel D: Input material for comparison or protein loading. For 
all panels representative images are shown for one of three independent experiments. 
Figure 9: Phospholamban Thr17, SERCA2a and Junctophilin-2 Levels are Increased in PKN1 
Knockout Hearts. Hearts were isolated from wild type (WT) and PKN1 knockout (KO) mice, 
subjected to SDS-PAGE and Western blotting. Panel A: Total PKN1, phospho- (Thr17) and 
total phospholamban (PLB), SERCA2a, phospho- (Thr287) and total CamKII junctophilin-2 
(Jph2) and the Na+/K+ ATPase (NKA). GAPDH was used as a loading control. Panel B: 
Quantitative analysis of levels and statistical analysis using an unpaired T-test where 
**p<0.01. Proteins were quantitated by densitometry and normalised to total GAPDH and 
compared using a two-tailed unpaired T-test (n=4 individual hearts). Each sample represents 
a different lysate prepared from an individual heart.  
Figure 10: Echocardiographic and P-V Loop Analysis of Cardiac Contractile Function Shows 
Mild Diastolic Dysfunction in PKN1 KO Hearts. Panel A: Differences in left ventricular (LV) 
posterior wall thickness at diastole (PWTD) between wild type (WT: n=7) and knockout (KO: 
n=5) mice derived from Doppler echocardiography. Panel B: Relationships between systolic 
pressure (SP), maximal rate of contraction (dP/dT max) and maximal rate of relaxation (dP/dT 
min) and end diastolic pressure (EDP) in WT (n=4) and PKN1 KO (n=5) hearts derived from 
PV loop analysis. Panel C: Correlation of beat-to-beat differences in LV SP versus EDP for 
a single WT and PKN1 KO mouse derived from PV loop analysis. Panel D: Comparison of 




correlation coefficients (R2) for SP/EDP, dP/dT max/EDP and dP/dT min/EDP for WT (n=4) 
and PKN1 KO (n=5) mice derived from PV loop analysis. 
 
